5 Key Takeaways

• 1

  Vitiligo lacks standardized definitions of severity and relapse, complicating treatment strategies and patient management.

• 2

  Recent therapeutic advances, including JAK inhibitors, have not been adequately assessed for relapse due to inconsistent definitions.

• 3

  An international consensus statement aims to establish body surface area-based severity strata and define relapse more clearly.

• 4

  The new framework represents a shift towards multidimensional assessments, incorporating both psychological and clinical factors.

• 5

  Applying the consensus criteria consistently in clinical trials and practice is the next challenge for managing vitiligo.